Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.carrev.2019.04.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comment: Analysis of Bicarbonate-Based Purge Solution in Patients With Cardiogenic Shock Supported Via Impella Ventricular Device.
Ann Pharmacother
September 2023
Abiomed, Danvers, MA, USA.
Letter by Bilazarian et al. regarding the article, "Adverse events and modes of failure related to Impella RP: Insights from the Manufacturer and User Facility Device Experience (MAUDE) database" by Khalid et al.
Cardiovasc Revasc Med
July 2019
Abiomed, Inc., Danvers, MA, United States of America.
Vorapaxar in the secondary prevention of atherothrombotic events.
N Engl J Med
April 2012
Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Background: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1.
Methods: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!